Skip to main content
Inventiva S.A. logo

Inventiva S.A. — Investor Relations & Filings

Ticker · IVA ISIN · US46124U1079 US Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2026-06-03 Proxy Solicitation & In…
Country US United States of America
Listing US IVA

About Inventiva S.A.

https://inventivapharma.com/

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies that target nuclear receptors and transcription factors. The company's primary focus is on diseases with significant unmet medical needs, including fibrosis and metabolic disorders. Its lead product candidate, lanifibranor, is a pan-PPAR agonist in development for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including inflammation, steatosis, ballooning, and fibrosis. Following positive Phase IIb results, the U.S. Food and Drug Administration (FDA) granted lanifibranor Breakthrough Therapy Designation. The candidate is currently being evaluated in a pivotal Phase III clinical trial (NATiV3).

Recent filings

Filing Released Lang Actions
FORM 6-K
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a Form 6-K report of a foreign private issuer, Inventiva S.A., primarily furnishing its proxy card and voting instructions (Exhibits 99.1 and 99.2) for an upcoming Ordinary and Extraordinary General Meeting. These exhibits are materials sent to shareholders to inform them and solicit votes for the meeting, fitting the definition of Proxy Solicitation & Information Statement (PSI).
2026-06-03 English
FORM 6-K
Capital/Financing Update Classification · 85% confidence The document is a Form 6-K current report by a foreign private issuer filed under the SEC’s Exchange Act, and the substance is a comprehensive refinancing transaction including a share offering, loan repayment, debt financing facility, warrant repurchase and issuance. This is not an earnings release or quarterly report, but a detailed update on capital raising and capital structure. It therefore matches the definition of a Capital/Financing Update (CAP).
2026-06-02 English
424B5
Share Issue/Capital Change Classification · 88% confidence The document is a Form 424B5 prospectus supplement to a June 2, 2026 prospectus under a shelf registration (Form F-3) describing an offering of 27,272,727 American Depositary Shares (ADSs) and related financing terms. It is not a management or earnings report, call transcript, or proxy; rather, it is the formal offering document for a new share issuance. Under our taxonomy, announcements or formal documents detailing new share issues or capital changes fall under Share Issue/Capital Change (SHA).
2026-06-02 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) detailing a comprehensive refinancing transaction: new debt financing, equity offering, warrant repurchases, and capital structure changes. It focuses on fundraising and capital structure optimization rather than reporting financial results, management discussion, or regulatory compliance. This matches the definition of a Capital/Financing Update (CAP).
2026-06-02 English
FORM 6-K
Regulatory Filings Classification · 75% confidence The document is a Form 6-K filing by a foreign private issuer under the Securities Exchange Act, providing a press release as Exhibit 99.1. It contains no standalone financial statements or substantive report content but serves as a regulatory submission of an attached press release. Under the classification rules, Form 6-K filings that furnish external documents fall into the general regulatory filings category (RNS).
2026-05-26 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a Form 6-K filing by a foreign private issuer (Inventiva S.A.) furnishing Notice of Meeting materials for its Ordinary and Extraordinary General Meeting. This notice is a shareholder solicitation and information statement for voting at the upcoming meeting. Under our taxonomy, materials sent to shareholders to provide information and request votes at a meeting fall under Proxy Solicitation & Information Statement (PSI).
2026-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.